Surgeons remodel and replace man's jaw bone allowing him to eat first dinner in 9 years

“By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup”.

A new procedure for creating and transplanting bone grafts is detailed by German authors of a study in this week’s issue of THE LANCET.

One of the drawback’s of bone transplantation from one part of the body to another is the creation of a secondary bone defect to treat the primary defect. Patrick H Warnke (Department of Oral and Maxillofacial Surgery, University of Kiel, Germany) and colleagues treated a 56-year-old man who had had part of his jaw bone removed due to cancer. Rather than obtaining a graft from another part of the patient’s body (such as the hip bone), the investigators used 3D computed tomography (CT) scanning and computer-aided design techniques to produce a replacement for the jaw-bone defect. These data were used to create a titanium mesh cage that was filled with bone mineral blocks and 7 mg recombinant human bone morphogenetic protein 7 and 20 mL of the patient’s bone marrow. The transplant was implanted into the muscle below the patient’s right shoulder blade (latissimus dorsi muscle); 7 weeks later the new bone graft was transplanted as a free bone-muscle flap to repair the jaw-bone defect.

Bone remodelling and mineralisation inside the transplant were evident both before and after transplantation. CT provided radiological evidence of new bone formation. The patient regained the ability to chew; by the 4th week posttransplantation he enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup.

Dr Warnke comments: “To the best of our knowledge, this case provides evidence that heterotopic bone induction to form a mandibular replacement inside the latissimus dorsi muscle in a human being with a prefabrication technique is possible. The prefabrication technique described, and subsequent free-flap reconstruction of the mandible, allows for a lower operative burden and a better three-dimensional outcome than conventional reconstruction techniques. We suggest that our results represent a proof of principle. Many vital questions still remain unanswered. The exciting nature of the result achieved in this patient to date has prompted our group to extend this trial to include additional patients. For us to draw firm conclusions, an extended period of follow-up is necessary. We hope to present this patient’s long-term outcome and those of future patients at a later date”.

Stan Gronthos (Hanson Institute, Adelaide, Australia) concludes in an accompanying commentary: “There is little doubt that scientists and clinicians alike will continue to challenge the benefits and merits of novel regenerative medical procedures for some time to come. Appropriate combinations of bioengineering (biomaterials, growth factors, and stem cells) are essential for stable long-term function and integration of therapeutic implants. Meanwhile, as the debates continue, a patient who had previously lost his mandible through the result of a destructive tumour can now sit down to chew his first solid meals in 9 years, courtesy of a new mandible-like structured implant, resulting in an improved quality of life for that individual”.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experimental drug RK-33 shows promise in treating breast cancer bone metastasis